5 results about "Leukocytopenia" patented technology

This invention discloses a method for preparing pet stem cell exosomes, belonging to the field of animal medicine technology. This invention treats stem cells with an inducing agent to secrete exosomes with high TFR expression on their surface. These exosomes specifically target the conserved region of the NS1 gene, a non-structural protein of the parvovirus family, allowing the internally loaded siRNA and trefoil factor 3 to target and enter infected cells, directly inhibiting viral replication at the gene level to treat feline panleukopenia virus (FPV) and canine parvovirus infections and alleviate sequelae. This invention solves the problems of existing technologies, such as difficulty in targeting, lack of specific drugs, reliance on intensive supportive care leading to a short treatment window, inability to directly clear the virus, risk of cross-infection, and potential long-term sequelae. It has the potential to be applied to the preparation of drugs for treating canine parvovirus and feline panleukopenia.

The invention discloses an innovative application of pseudo-ginsenoside RT5 in preparation of leukocyte increasing drugs and tumor treatment support drugs. The medicine is used for treating or relieving myelosuppression leucopenia induced by chemotherapeutic medicines (such as etoposide). The invention creatively discovers that the pseudo-ginsenoside RT5 can remarkably improve the level of neutrophil caused by myelosuppression and effectively relieve the side effect of chemotherapy, and experiments prove that the pseudo-ginsenoside RT5 remarkably prolongs the survival time under the influence of chemotherapy drugs. The effectiveness of the method is analyzed based on an etoposide myelosuppression model and survival time of zebrafish fries. As the pseudo-ginsenoside RT5 is derived from a natural component of homology of medicine and food (such as American ginseng), the pseudo-ginsenoside RT5 has the advantages of high safety and suitability for long-term drug combination, the chemotherapy compliance and the curative effect can be remarkably improved, and a novel efficient and low-toxicity support drug is provided for overcoming myelosuppression in tumor chemotherapy.

The invention discloses a feline panleucopenia virus RNA vaccine and application thereof, and relates to the technical field of veterinary biological products. The saRNA prepared by adopting the nucleic acid molecule provided by the invention can secrete a higher-level feline panleukopenia virus VP2 protein antigen after transfecting cells. After the optimized feline panleucopenia virus VP2 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the effect of preventing the feline panleucopenia virus is achieved. Therefore, the nucleic acid molecule provided by the invention can be used for developing recombinant protein vaccines or preparing nucleic acid vaccines. Animal experiment results prove that the feline panleukopenia virus mRNA has good immunogenicity and safety compared with a traditional vaccine, and has a good application prospect.

The invention discloses a chimeric monoclonal antibody specifically combined with feline parvovirus and application of the chimeric monoclonal antibody, and belongs to the technical field of antibody engineering. The chimeric monoclonal antibody is formed by chimeric combination of a mouse source monoclonal antibody variable region and a cat source antibody constant region; the variable region of the mouse monoclonal antibody comprises a heavy chain variable region with a sequence as shown in SEQ ID NO.3 and a light chain variable region with a sequence as shown in SEQ ID NO.4. The hemagglutination inhibition titer of the chimeric monoclonal antibody against FPV reaches 1: 4194304, IC50 is 0.0008 mg / mL, and the chimeric monoclonal antibody can completely protect an FPV infected cat model and has broad-spectrum neutralizing activity on various parvovirus variants. The invention fills the blank of the current specific therapeutic drug for feline panleucopenia, and has the advantages of high efficiency, low immunogenicity and large-scale production.

The invention discloses a neutralizing monoclonal antibody for resisting feline panleucopenia virus and application of the neutralizing monoclonal antibody, and belongs to the technical field of bioengineering. The antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and amino acid sequences of the heavy chain variable region (VH) and the light chain variable region (VL) are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2; the antibody is an IgG2a subtype and kappa light chain, can specifically bind to FPV VP2 protein, and effectively neutralizes infection of an F81 cell by an FPV-ZZ20230 strain under the dilution ratio of 1: 64. The invention also provides nucleic acid molecules (SEQ ID NO: 8-9) for coding the antibody, an expression vector, a host cell and a preparation method. The antibody can be used for preparing medicines for preventing or treating feline panleucopenia, and can also be used as a detection antibody for ELISA (enzyme-linked immuno sorbent assay), Western blot or indirect immunofluorescence (IFA) diagnostic kits. The antibody is clear in structure and high in neutralizing activity, does not need to be preserved by hybridoma, and has good clinical application and industrialization prospects.